[Experimental chemotherapy of Proteus vulgaris infection].
D000667:Ampicillin / Q000494:pharmacology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002509:Cephaloridine / Q000494:pharmacology; D002512:Cephalothin / Q000494:pharmacology; D002701:Chloramphenicol / Q000494:pharmacology; D003091:Colistin / Q000494:pharmacology; D004917:Erythromycin / Q000494:pharmacology; D005839:Gentamicins / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D007279:Injections, Subcutaneous; D007612:Kanamycin / Q000494:pharmacology; D007933:Leucomycins / Q000494:pharmacology; D051379:Mice; D009268:Nalidixic Acid / Q000494:pharmacology; D009675:Novobiocin / Q000494:pharmacology; D009827:Oleandomycin / Q000494:pharmacology; D010303:Paromomycin / Q000494:pharmacology; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology; D011113:Polymyxins / Q000494:pharmacology; D011511:Proteus / Q000187:drug effects*; D011512:Proteus Infections / Q000188:drug therapy*; D013307:Streptomycin / Q000494:pharmacology; D013752:Tetracycline / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D007933:Leucomycins; D010406:Penicillins; D011113:Polymyxins; D009675:Novobiocin; D009268:Nalidixic Acid; D007612:Kanamycin; D010303:Paromomycin; D004917:Erythromycin; D002701:Chloramphenicol; D000667:Ampicillin; D013752:Tetracycline; D002509:Cephaloridine; D009827:Oleandomycin; D002512:Cephalothin; D013307:Streptomycin; D003091:Colistin